Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Gut bacterial metabolite worsens brain damage after stroke, study finds (opens in a new tab)

news-medical.net · 2026-10-01

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 2 supported
  • 3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Two of five claims match the study. This overall rating is based only on the claims we could check. Three claims the study doesn't address.

  • 2 supported
  • 3 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredIn mice with severe stroke, gut bacteria capable of producing indole became more abundant, and indole-producing bacteria worsened brain injury after stroke.View evidenceHide evidence

Why this verdict

The causal part of the claim—that indole-producing E. coli/indole can worsen ischemic stroke outcomes in mice—is supported by the abstract-level mouse intervention and epistasis summaries. However, the more specific wording that such bacteria ‘became more abundant’ in mice with ‘severe stroke’ is not verifiable from the abstract-level profile, which reports enrichment/association with worse outcomes but not the temporal abundance-change details.

1

Study evidence

Enrichment or colonization of mice with indole-producing Escherichia coli, and administration of indole, were associated with worse outcomes after experimental ischemic stroke.

“we identify the enrichment of indole-producing Escherichia coli being associated with worse outcomes in mice”
2

Study evidence

DC-specific deletion of AHR attenuated the detrimental effects on ischemic stroke outcomes caused by (a) colonization with indole-producing Escherichia coli, (b) administration of indole, and (c) fecal microbiota transplantation from patients with stroke.

“Detrimental effects of indole-producing Escherichia coli, indole administration, and microbiota transplantation from patients with stroke are attenuated in DC-specific AHR-deficient mice.”
Claim 2 of 5Not coveredIn a cohort of human patients with ischemic stroke, higher abundance of bacterial TnaA was associated with poorer functional outcome.View evidenceHide evidence

Why this verdict

The paper profile supports an observational human association between enrichment of indole-producing E. coli and worse ischemic stroke outcomes. But the claim’s specific marker wording—higher abundance of bacterial TnaA and poorer functional outcome—is not present in the abstract-level profile, so that level of specificity is not verifiable at this depth.

1

Study evidence

In the patient cohort, enrichment of indole-producing Escherichia coli in the gut microbiota was associated with worse ischemic stroke outcomes.

“we identify the enrichment of indole-producing Escherichia coli being associated with worse outcomes in mice and patients with ischemic stroke.”
Claim 3 of 5Not coveredThe article says bacteria carrying the tnaA gene were also more abundant in people with stroke risk factors such as obesity and type 2 diabetes.View evidenceHide evidence

Why this verdict

The abstract-level paper profile does not report whether tnaA-carrying bacteria were more abundant in people with stroke risk factors such as obesity or type 2 diabetes. This may require full-text evidence, but it is not verifiable from the supplied abstract-depth profile.

Claim 4 of 5SupportedResearchers at LMU say they discovered how a metabolite produced by gut bacteria can influence brain damage after stroke.View evidenceHide evidence

Why this verdict

At abstract depth, the paper supports a causal mouse-mechanism claim: microbial indole/indole-producing E. coli worsened experimental ischemic stroke outcomes, and DC-specific AHR experiments support an AHR-dependent mechanism in dendritic cells. The story’s caveats, as supplied, note that the mechanism remains to be determined in patients, so the lead does not necessarily convert the mouse causal evidence into a human causal claim.

1

Study evidence

Enrichment or colonization of mice with indole-producing Escherichia coli, and administration of indole, were associated with worse outcomes after experimental ischemic stroke.

“we identify the enrichment of indole-producing Escherichia coli being associated with worse outcomes in mice”
2

Study evidence

DC-specific AHR deletion improves ischemic stroke outcomes and preserves intestinal conventional type 1 dendritic cells (cDC1) in mice.

“DC-specific AHR deletion improves stroke outcomes and preserves intestinal conventional type 1 DCs.”
Claim 5 of 5SupportedThe study says indole acts on AHR in intestinal dendritic cells, and switching off AHR specifically in dendritic cells protected mice against brain injury.View evidenceHide evidence

Why this verdict

The abstract-level profile directly supports this: microbial indole triggers an AHR-dependent response in dendritic cells, DC-specific AHR deletion improves mouse stroke outcomes, and harmful effects of indole-producing E. coli/indole are attenuated in DC-specific AHR-deficient mice.

1

Study evidence

DC-specific AHR deletion improves ischemic stroke outcomes and preserves intestinal conventional type 1 dendritic cells (cDC1) in mice.

“DC-specific AHR deletion improves stroke outcomes and preserves intestinal conventional type 1 DCs.”
2

Study evidence

DC-specific deletion of AHR attenuated the detrimental effects on ischemic stroke outcomes caused by (a) colonization with indole-producing Escherichia coli, (b) administration of indole, and (c) fecal microbiota transplantation from patients with stroke.

“Detrimental effects of indole-producing Escherichia coli, indole administration, and microbiota transplantation from patients with stroke are attenuated in DC-specific AHR-deficient mice.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Additional mechanistic immune-pathway findings: AHR loss/inhibition promotes immunoregulatory and migratory dendritic-cell programs, CCR7-dependent migration, meningeal gut-derived DC accumulation, increased Tregs, and reduced neuroinflammation.

    The story broadly says the pathway can influence post-stroke immune responses, but the supplied presentation does not reflect these more specific mechanistic findings.

    From Transcriptomic profiling of DCs (AHR deletion vs control); In vitro CCR7-dependent migration assay (transwell/chemotaxis

  • Treg necessity experiment: Treg depletion abolishes the neuroprotection conferred by AHR inhibition in mice.

    This causal/mediation experiment is a material mechanistic result in the paper profile, but it is not mentioned in the supplied story presentation.

    From Treg depletion necessity experiment

  • Epistasis/FMT evidence: detrimental effects of indole-producing E. coli, indole administration, and microbiota transplantation from stroke patients are attenuated in DC-specific AHR-deficient mice.

    The story reflects the general DC-AHR mechanism but does not mention the patient microbiota transplantation or the grouped genotype-by-exposure attenuation evidence.

    From in_vivo genotype×exposure interaction (conditional DC-specific AHR deletion)

3 things the story did carry across
  • Mouse experimental evidence that indole-producing E. coli and/or indole exposure worsens ischemic stroke outcomes.
  • Mechanistic mouse evidence that microbial indole acts through AHR-dependent signaling in dendritic cells, and that DC-specific AHR deletion improves stroke outcomes.
  • Human ischemic stroke evidence is observational: enrichment of indole-producing E. coli is associated with worse outcomes, without establishing human causality.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

8

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalMicrobial indole worsens stroke via an AHR-dependent program in intestinal dendritic cells; DC-specific AHR deletion is protective and preserves intestinal cDC1.Conditional DC-specific AHR knockout in mice; in vivo ischemic stroke model; intestinal DC immunophenotypingExpand

In plain English

In mice, conditional deletion of the aryl hydrocarbon receptor (AHR) specifically in dendritic cells (DCs) improved ischemic stroke outcomes and preserved intestinal conventional type 1 dendritic cells (cDC1).

Key findings

  • DC-specific AHR deletion improves ischemic stroke outcomes and preserves intestinal conventional type 1 dendritic cells (cDC1) in mice.
“DC-specific AHR deletion improves stroke outcomes and preserves intestinal conventional type 1 DCs.”
What this piece can’t prove
  • The abstract does not provide detailed information on strain, sex, age of mice, or timing relative to stroke, limiting assessment of generalizability.

1 further detail could not be confirmed from the summary.

2human in vivoIndole-producing Escherichia coli (and microbiota enriched for indole production) is associated with worse ischemic stroke outcomes in mice and in human patients.observational cohortExpand

In plain English

In a human ischemic stroke cohort, the authors report that enrichment of indole-producing Escherichia coli in the gut microbiota was associated with worse clinical outcomes after ischemic stroke (observational association described in the abstract).

Key findings

  • In the patient cohort, enrichment of indole-producing Escherichia coli in the gut microbiota was associated with worse ischemic stroke outcomes.
“we identify the enrichment of indole-producing Escherichia coli being associated with worse outcomes in mice and patients with ischemic stroke.”
What this piece can’t prove
  • Abstract lacks methodological details (sample size, sequencing or functional assay methods, timing of sampling relative to stroke, statistical models and covariate adjustment).
  • Unclear whether 'indole-producing' designation was directly measured or inferred from taxonomic/functional profiling.

2 further details could not be confirmed from the summary.

3in vivo animalIndole-producing Escherichia coli (and microbiota enriched for indole production) is associated with worse ischemic stroke outcomes in mice and in human patients.in vivo mouse microbiota manipulation strokeExpand

In plain English

In mouse ischemic stroke models, enrichment or colonization with indole-producing Escherichia coli and administration of the microbial metabolite indole are reported to be associated with worse stroke outcomes (infarct/neurobehavioral severity).

Key findings

  • Enrichment or colonization of mice with indole-producing Escherichia coli, and administration of indole, were associated with worse outcomes after experimental ischemic stroke.
“we identify the enrichment of indole-producing Escherichia coli being associated with worse outcomes in mice”
What this piece can’t prove
  • Findings are from a mouse model and may not directly translate to humans without additional evidence.

2 further details could not be confirmed from the summary.

4ex vivo animalAHR loss/inhibition promotes immunoregulatory and migratory dendritic-cell programs (including CCR7-dependent migration) and alters CNS border immunity (meningeal gut-derived DCs, increased Tregs, reduced neuroinflammation).Transcriptomic profiling of DCs (AHR deletion vs control)Expand

In plain English

Transcriptomic profiling of dendritic cells from mice with DC-specific AHR deletion versus controls showed enrichment of immunoregulatory and migratory transcriptional signatures.

Key findings

  • Deletion of AHR in dendritic cells is associated with transcriptional signatures interpreted as immunoregulatory and migratory.
“AHR deletion also promotes immunoregulatory and migratory transcriptional signatures”
What this piece can’t prove
  • Unclear whether profiles reflect bulk-sorted DC populations or single-cell resolution; potential heterogeneity within DC subsets may affect interpretation.
  • Abstract does not report specific differentially expressed genes, effect sizes, or multiple-testing correction parameters for the transcriptional analyses.

1 further detail could not be confirmed from the summary.

5in vitroAHR loss/inhibition promotes immunoregulatory and migratory dendritic-cell programs (including CCR7-dependent migration) and alters CNS border immunity (meningeal gut-derived DCs, increased Tregs, reduced neuroinflammation).In vitro CCR7-dependent migration assay (transwell/chemotaxis)Expand

In plain English

In an in vitro chemotaxis assay, dendritic cells lacking AHR showed increased CCR7-dependent migration compared with control DCs.

Key findings

  • AHR deletion enhances CCR7-dependent migration of dendritic cells in vitro.
“and enhances CCR7-dependent migration in vitro.”
What this piece can’t prove
  • DC source (tissue, species/strain, maturation state) and exact assay conditions are not specified.
  • Generalisability to in vivo migration or functional consequences beyond the assay are not addressed in this unit.

1 further detail could not be confirmed from the summary.

6in vivo animalAHR loss/inhibition promotes immunoregulatory and migratory dendritic-cell programs (including CCR7-dependent migration) and alters CNS border immunity (meningeal gut-derived DCs, increased Tregs, reduced neuroinflammation).pharmacological in vivo interventionExpand

In plain English

In a mouse ischemic stroke model, pharmacological inhibition of the aryl hydrocarbon receptor (AHR) favored accumulation of gut-derived dendritic cells (DCs) in the meninges and was accompanied by increased regulatory T cells (Tregs) and reduced neuroinflammation. These observations were reported from in vivo drug-based AHR inhibition with immunological readouts at CNS borders; the abstract does not report quantitative effect sizes, dosing/timing details, or sample sizes.

Key findings

  • Pharmacological AHR inhibition promotes accumulation of gut-derived dendritic cells in the meninges after experimental stroke.
  • AHR inhibition is accompanied by increased regulatory T cell (Treg) frequency/numbers at CNS borders.
“Pharmacological AHR inhibition favors gut-derived DC accumulation in the meninges, accompanied by increased regulatory T cells (Tregs) and reduced neuroinflammation”
What this piece can’t prove

4 further details could not be confirmed from the summary.

7in vivo animalThe neuroprotection from AHR inhibition depends on regulatory T cells (Treg depletion abolishes protection).Treg depletion necessity experimentExpand

In plain English

In a mouse ischemic stroke model, depletion of regulatory T cells (Tregs) eliminated the neuroprotective effect conferred by pharmacological AHR inhibition, indicating that Tregs are necessary for AHR-inhibition–mediated neuroprotection (abstract).

Key findings

  • Depleting regulatory T cells abolishes the neuroprotection otherwise conferred by AHR inhibition in mice subjected to ischemic stroke (abstract).
“while Treg depletion abolishes the neuroprotection conferred by AHR inhibition.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

8in vivo animalCausality/epistasis: detrimental effects of indole-producing E. coli, indole administration, and patient microbiota transfer are attenuated when DC-AHR is deleted.in vivo genotype×exposure interaction (conditional DC-specific AHR deletion)Expand

In plain English

In a mouse model with dendritic cell (DC)-specific AHR deletion, the harmful effects on ischemic stroke outcomes produced by exposure to indole-producing Escherichia coli, by administration of indole, or by fecal microbiota transplantation (FMT) from patients with stroke were attenuated, consistent with a genotype-by-exposure interaction in which DC AHR mediates microbiota/indole-driven worsening of stroke.

Key findings

  • DC-specific deletion of AHR attenuated the detrimental effects on ischemic stroke outcomes caused by (a) colonization with indole-producing Escherichia coli, (b) administration of indole, and (c) fecal microbiota transplantation from patients with stroke.
“Detrimental effects of indole-producing Escherichia coli, indole administration, and microbiota transplantation from patients with stroke are attenuated in DC-specific AHR-deficient mice.”
What this piece can’t prove
  • Abstract does not report quantitative effect sizes, confidence intervals, or statistical significance values for the genotype × exposure interaction.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 36 candidate papers

And 30 more candidates considered.